Lantheus (LNTH) PT Lowered to $21.00 at Credit Suisse Group

Lantheus (NASDAQ:LNTH) had its price target cut by Credit Suisse Group from $23.00 to $21.00 in a research note published on Thursday, August 2nd. They currently have a neutral rating on the medical equipment provider’s stock.

A number of other research firms have also recently issued reports on LNTH. Zacks Investment Research upgraded Lantheus from a sell rating to a hold rating in a report on Wednesday, May 2nd. BidaskClub upgraded Lantheus from a hold rating to a buy rating in a report on Tuesday, May 1st. Finally, ValuEngine upgraded Lantheus from a sell rating to a hold rating in a report on Thursday, August 2nd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $23.75.

Lantheus traded down $0.40, reaching $13.10, during trading hours on Thursday, according to Marketbeat Ratings. 228,163 shares of the company’s stock traded hands, compared to its average volume of 296,012. Lantheus has a 52-week low of $13.00 and a 52-week high of $24.45. The company has a quick ratio of 3.14, a current ratio of 3.86 and a debt-to-equity ratio of 5.94. The stock has a market cap of $517.05 million, a P/E ratio of 16.07, a PEG ratio of 1.29 and a beta of 1.28.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, August 1st. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.04. Lantheus had a return on equity of 560.19% and a net margin of 37.53%. The company had revenue of $85.60 million during the quarter, compared to analysts’ expectations of $87.90 million. During the same quarter in the previous year, the business earned $0.35 EPS. Lantheus’s revenue was down 3.6% compared to the same quarter last year. equities analysts anticipate that Lantheus will post 0.87 EPS for the current fiscal year.

In other news, Director Julie Mchugh sold 4,560 shares of the firm’s stock in a transaction that occurred on Monday, June 25th. The stock was sold at an average price of $14.72, for a total value of $67,123.20. Following the transaction, the director now owns 14,752 shares in the company, valued at $217,149.44. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.20% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. Piedmont Investment Advisors LLC acquired a new stake in shares of Lantheus during the 2nd quarter worth $104,000. NumerixS Investment Technologies Inc increased its holdings in shares of Lantheus by 1,000.0% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 7,700 shares of the medical equipment provider’s stock worth $113,000 after buying an additional 7,000 shares during the last quarter. Sun Life Financial INC acquired a new stake in Lantheus in the 2nd quarter valued at $140,000. SG Americas Securities LLC acquired a new stake in Lantheus in the 2nd quarter valued at $151,000. Finally, MetLife Investment Advisors LLC acquired a new stake in Lantheus in the 4th quarter valued at $267,000. 93.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Read More: How to Use the New Google Finance Tool

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with's FREE daily email newsletter.

Leave a Reply